Patents Assigned to Enzo Biochem, Inc.
  • Patent number: 11938167
    Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: March 26, 2024
    Assignees: ENZO BIOCHEM, INC., ENZO THERAPEUTICS, INC.
    Inventors: Joshua Rabbani, Xiaofeng Li, James J. Donegan
  • Patent number: 11931344
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: March 19, 2024
    Assignee: ENZO BIOCHEM, INC.
    Inventor: Elazar Rabbani
  • Publication number: 20240024259
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: July 28, 2023
    Publication date: January 25, 2024
    Applicant: ENZO BIOCHEM, INC.
    Inventors: Elazar RABBANI, James J. DONEGAN
  • Patent number: 11865105
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 9, 2024
    Assignee: ENZO BIOCHEM, INC.
    Inventors: Elazar Rabbani, James J. Donegan
  • Publication number: 20230364145
    Abstract: The invention provides cell culture compositions for regulatory T-cells that include particular synthetic peptides. Also provided are methods of treating autoimmune diseases such as age-related macular degeneration and uveitis with regulatory T-cells prepared using said compositions.
    Type: Application
    Filed: July 26, 2023
    Publication date: November 16, 2023
    Applicant: ENZO BIOCHEM, INC.
    Inventors: Robert NUSSENBLATT, Baoying LIU, Lai WEI, Elazar RABBANI, James J. DONEGAN
  • Patent number: 11723895
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: August 15, 2023
    Assignee: ENZO BIOCHEM, INC.
    Inventor: Elazar Rabbani
  • Patent number: 11667703
    Abstract: Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds which disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: June 6, 2023
    Assignee: ENZO BIOCHEM, INC.
    Inventor: Joshua Rabbani
  • Publication number: 20230158003
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: January 11, 2023
    Publication date: May 25, 2023
    Applicant: Enzo Biochem, Inc.
    Inventor: Elazar Rabbani
  • Patent number: 11639382
    Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. In one embodiment, the Wnt pathway protein is the Dickkopf1 (Dkk1) protein. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, such as a Dkk1, wherein the fragment is sulfated.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: May 2, 2023
    Assignee: ENZO BIOCHEM, INC.
    Inventors: Joshua Rabbani, James J. Donegan
  • Patent number: 11554111
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: January 17, 2023
    Assignee: ENZO BIOCHEM, INC.
    Inventor: Elazar Rabbani
  • Publication number: 20230002805
    Abstract: The invention provides methods for accelerated synthesis of nucleic acids, and related compositions which involve the use of organic amines in the nucleic acid synthesis reaction mixture. The invention also provides methods for reducing processing steps associated with nucleic acid synthesis. The invention further provides methods for screening compounds that have positive benefits on the synthesis of nucleic acids.
    Type: Application
    Filed: December 15, 2021
    Publication date: January 5, 2023
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jack Coleman
  • Publication number: 20220025188
    Abstract: The invention provides chemical conjugates comprising a plurality of fluorescence quenching moieties conjugated to polymer and the use of such conjugates to quench the emission of fluorescence from emitters including macromolecular fluorescent emitters such as phycoerythrin.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 27, 2022
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jack Coleman
  • Publication number: 20220023402
    Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
    Type: Application
    Filed: October 12, 2021
    Publication date: January 27, 2022
    Applicant: Enzo Biochem, Inc.
    Inventors: Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
  • Publication number: 20220023383
    Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Applicants: Enzo Biochem, Inc, Enzo Therapeutics, Inc.
    Inventors: Joshua Rabbani, Xiaofeng Li, James J. Donegan
  • Patent number: 11173195
    Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and transforming growth factor beta, (TGF-?).
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: November 16, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
  • Patent number: 11167011
    Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: November 9, 2021
    Assignees: Enzo Biochem, Inc., Enzo Theuraputics, Inc.
    Inventors: Joshua Rabbani, Xiaofeng Li, James J. Donegan
  • Publication number: 20210301357
    Abstract: The invention provides comprehensive and comparative flow cytometry-based methods for characterizing the state of a biological system by determining cell phenotypes and associated gene expression profiles.
    Type: Application
    Filed: May 4, 2021
    Publication date: September 30, 2021
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan, Andrew Stewart L'Huillier
  • Publication number: 20210290567
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: March 10, 2021
    Publication date: September 23, 2021
    Applicant: Enzo Biochem, Inc.
    Inventor: Elazar Rabbani
  • Publication number: 20210290600
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: March 10, 2021
    Publication date: September 23, 2021
    Applicant: Enzo Biochem, Inc.
    Inventor: Elazar Rabbani
  • Patent number: 11066694
    Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: July 20, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo